Trial Profile
Enzalutamide treatment sensitivity recovery effect of docetaxel treatment after relapse of enzalutamide treatment for castration-resistant prostate cancer patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2020
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ESRED
- 16 Oct 2020 Status changed from recruiting to discontinued.
- 18 Nov 2015 Status changed from not yet recruiting to recruiting, according to University Hospital Medical Information Network - Japan record.
- 06 Nov 2015 New trial record